Ligand Pharmaceuticals

• NCT04629976

  Collaborator, Phase 1, Completed, 21 people, 16 Nov 2020

• NCT00940953

  Phase 2, Completed, 108 people, 17 Jul 2009

• NCT00938613

  Phase 2, Completed, 65 people, 14 Jul 2009

• NCT00238628

  Collaborator, Phase 1/2, Completed, 6 people, 13 Oct 2005

• NCT00163137

  Phase 3, Completed, 540 people, 13 Sept 2005

• NCT00006345

  Phase 2, Completed, 25 Mar 2004

• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

  Consulting or advice, Fees or honoraria, Grants or research support, 1 Feb 2021

Sources: pubmed.ncbi.nlm.nih.gov